Drug intelligence / Profile preview

Suplineuro LC

Development stage
Unknown
Lead developer
Neurogenics Therapeutics
Modality
Small Molecules
Administration
Oral
01

Overview

Suplineuro LC is a fixed-dose combination nutraceutical developed by Neurogenics Therapeutics, primarily indicated for the management of peripheral and diabetic neuropathy. The product contains levocarnitine, methylcobalamin, and folic acid. Levocarnitine facilitates the transport of long-chain fatty acids into mitochondria, supporting energy production essential for nerve cell repair and function. Methylcobalamin, an active form of Vitamin B12, promotes the synthesis of the myelin sheath and aids in nerve regeneration. Folic acid is a critical cofactor for DNA synthesis and the regulation of homocysteine levels, which, when elevated, can contribute to nerve damage. Together, these components work synergistically to alleviate neuropathic symptoms and improve overall nerve health.

Brand names
Suplineuro LC
Other names
levocarnitine + methylcobalamin + folic acid
02

Targets

MTR (Methionine synthase)SLC7A1 (Cationic amino acid transporter 1)DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on Suplineuro LC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suplineuro LC.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call